Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EADO 2022 | Prognostic factors of patients with squamous cell carcinoma undergoing a central lymph node biopsy

Antonio Tejera-Vaquerizo, MD, Instituto Dermatológico GlobalDerm, Córdoba, Spain, discusses a multicenter study, Squamous, conducted in Spain on the role of sentinel lymph node biopsy (SLNB) in squamous cell carcinoma (SCC). Via propensity score matching, 53 pairs of patients were matched. There has been no advantage observed for patients undergoing SLNB. Patients who had a positive SNLB had a worse prognosis. Patients who are immunosuppression also have worse prognosis and as such this patient population should be investigated further. This interview took place at the EADO 2022 congress.